228 related articles for article (PubMed ID: 16548909)
1. Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers.
Kitajima H; Takahashi H; Harada K; Kanai A; Inomata S; Taniguchi H; Saikai T; Abe S
Respirology; 2006 Mar; 11(2):217-20. PubMed ID: 16548909
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
3. Sudden onset of interstitial lung disease induced by gefitinib in a lung cancer patient with multiple drug allergy.
Aoe K; Hiraki A; Murakami T; Maeda T; Umemori Y; Katayama H; Eda R; Takeyama H
Anticancer Res; 2005; 25(1B):415-8. PubMed ID: 15816604
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases.
Ohnishi H; Yokoyama A; Kondo K; Hamada H; Abe M; Nishimura K; Hiwada K; Kohno N
Am J Respir Crit Care Med; 2002 Feb; 165(3):378-81. PubMed ID: 11818324
[TBL] [Abstract][Full Text] [Related]
5. [Clinical significance of serum KL-6 and SP-D for the diagnosis and treatment of interstitial lung disease in patients with diffuse connective tissue disorders].
Ogawa N; Shimoyama K; Kawabata H; Masaki Y; Wano Y; Sugai S
Ryumachi; 2003 Feb; 43(1):19-28. PubMed ID: 12692986
[TBL] [Abstract][Full Text] [Related]
6. [Diffuse lung diseases and biological markers in serum].
Takahashi H; Shiratori M
Nihon Naika Gakkai Zasshi; 2006 Jun; 95(6):986-92. PubMed ID: 16846044
[No Abstract] [Full Text] [Related]
7. Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease.
Al-Salmi QA; Walter JN; Colasurdo GN; Sockrider MM; Smith EO; Takahashi H; Fan LL
Chest; 2005 Jan; 127(1):403-7. PubMed ID: 15654008
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
[TBL] [Abstract][Full Text] [Related]
9. Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation.
Inoue A; Xin H; Suzuki T; Kanehira M; Kuroki Y; Fukuhara T; Kikuchi T; Maemondo M; Nukiwa T; Saijo Y
Cancer Sci; 2008 Aug; 99(8):1679-84. PubMed ID: 18754883
[TBL] [Abstract][Full Text] [Related]
10. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
Endo M; Johkoh T; Kimura K; Yamamoto N
Lung Cancer; 2006 May; 52(2):135-40. PubMed ID: 16574271
[TBL] [Abstract][Full Text] [Related]
11. [Assessment of serum markers KL-6 and SP-D for interstitial pneumonia associated with connective tissue diseases].
Suematsu E; Miyamura T; Shimada H; Nakao R; Yamamoto M
Ryumachi; 2003 Feb; 43(1):11-8. PubMed ID: 12692985
[TBL] [Abstract][Full Text] [Related]
12. Recurrent gefitinib-induced interstitial lung disease.
Suzuki M; Asahina H; Konishi J; Yamazaki K; Nishimura M
Intern Med; 2008; 47(6):533-6. PubMed ID: 18344641
[TBL] [Abstract][Full Text] [Related]
13. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
BMC Cancer; 2017 May; 17(1):302. PubMed ID: 28464801
[TBL] [Abstract][Full Text] [Related]
14. [Surfactant proteins-A and D as important serum markers for interstitial lung disease in patients with polymyositis or dermatomyositis].
Chen F; Shu XM; Wang DX; Xie Y; Wang GC
Zhonghua Yi Xue Za Zhi; 2012 Aug; 92(31):2182-5. PubMed ID: 23158422
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Takano T; Ohe Y; Kusumoto M; Tateishi U; Yamamoto S; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Tamura T; Kodama T; Saijo N
Lung Cancer; 2004 Jul; 45(1):93-104. PubMed ID: 15196739
[TBL] [Abstract][Full Text] [Related]
17. [The clinical study on KL-6 and SP-D in sera of patients with various pulmonary diseases].
Sugimoto H; Okada E; Hashimoto N; Suzuki S; Yoshida H; Totani Y; Ameshima S; Ishizaki T; Miyamori I
Rinsho Byori; 2000 Jun; 48(6):554-60. PubMed ID: 10897675
[TBL] [Abstract][Full Text] [Related]
18. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
Niho S; Kubota K; Goto K; Yoh K; Ohmatsu H; Kakinuma R; Saijo N; Nishiwaki Y
J Clin Oncol; 2006 Jan; 24(1):64-9. PubMed ID: 16382114
[TBL] [Abstract][Full Text] [Related]
19. A case of interstitial pneumonia caused by bucillamine: a study using serological markers.
Tanimura K; Shimizu M; Matsuhashi M; Shinohara M; Sagawa A
Mod Rheumatol; 2006; 16(1):39-43. PubMed ID: 16622723
[TBL] [Abstract][Full Text] [Related]
20. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
